Zoetis Inc. (ZTS) To Go Ex-Dividend on January 20th

Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Thursday, December 11th. Investors of record on Tuesday, January 20th will be paid a dividend of 0.53 per share on Tuesday, March 3rd. This represents a c) dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a 6.0% increase from Zoetis’s previous quarterly dividend of $0.50.

Zoetis has raised its dividend payment by an average of 0.2%per year over the last three years and has raised its dividend every year for the last 14 years. Zoetis has a dividend payout ratio of 31.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Zoetis to earn $6.75 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 31.4%.

Zoetis Price Performance

ZTS stock opened at $124.79 on Friday. Zoetis has a one year low of $115.25 and a one year high of $177.40. The firm has a 50-day moving average of $123.21 and a two-hundred day moving average of $139.49. The firm has a market capitalization of $54.99 billion, a PE ratio of 21.01, a P/E/G ratio of 2.53 and a beta of 0.97. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the firm posted $1.58 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that Zoetis will post 6.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ZTS shares. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Wednesday, December 3rd. Barclays initiated coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Finally, KeyCorp assumed coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating on the stock. Six research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.